<h4>Objective</h4>The increasing use of PSMA-PET/CT for restaging prostate cancer (PCa) leads to a patient shift from a non-metastatic situation based on conventional imaging (CI) to a metastatic situation. This evidence concerns the gene FOLH1 and prostate carcinoma.